EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"HDX Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TAE Life Sciences Announces Partnership with HDX Corporation for Launch of Boron Neutron Capture Therapy in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Biddle Sawyer Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAE Life Sciences' Research on Boronotyrosine (BTS) Drug Shows Promise in Advancing Cancer-Fighting Potential of BNCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by TAE Life Sciences

    Menu

    TAE Life Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TAE Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TAE Life Sciences' Research on Boronotyrosine (BTS) Drug Shows Promise in Advancing Cancer-Fighting Potential of BNCT

              Details:

              BPA (boronophenylalanine) is an engineered targeting boron pharmaceuticals to deliver the cellular precision and curative power of BNCT. It is being evaluated for the treatment of head and neck, brain, breast, melanoma and other cancers.

              Lead Product(s): P-Borono-L-Phenylalanine

              Therapeutic Area: Oncology Product Name: BAP

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TAE Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment

              Details:

              Under the agreement, Biddle will serve as the exclusive supplier of TC220, a proprietary boronated amino acid analog developed by TAE Life Sciences to support BNCT cancer treatment.

              Lead Product(s): TC-220

              Therapeutic Area: Oncology Product Name: TC220

              Highest Development Status: IND Enabling Product Type: Large molecule

              Recipient: Biddle Sawyer Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TAE Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TAE Life Sciences Announces Partnership with HDX Corporation for Launch of Boron Neutron Capture Therapy in South Korea

              Details:

              TLS will provide support and training to HDX and intends to work with HDX to develop a local-language training and clinical education base in the future. BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10.

              Lead Product(s): BNCT

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: HDX Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TAE Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness

              Details:

              Results indicate that boron-11 concentrations of 80.4 ppm from sodium borocaptate (BSH) or 86.9 ppm from 4-borono-L-phenylalanine (BPA) treatments did not affect the biological effectiveness of proton beams due to proton–boron reactions in the DU145 prostate cancer cell line.

              Lead Product(s): Proton Boron Capture-based Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY